Le Lézard
Classified in: Health, Covid-19 virus
Subject: AVO

Biden Supports Early COVID Treatment: Too Little, Too Late? Asks Doctors for Disaster Preparedness


TUCSON, Ariz., Jan. 20, 2022 /PRNewswire/ -- In his Jan 19 press conference, President Joe Biden pushed for vaccinating everyone against COVID-19, including babies as soon as the science shows it to be safe, as it presumably will. But he also mentioned treatment for patients who nonetheless become infected, observes Doctors for Disaster Preparedness (DDP) president Jane Orient, M.D.

"Additionally, we're increasing the availability of new medicines recommended by real doctors, not conspir?conspiracy theorists." At the press conference, he specifically named monoclonal antibodies and alluded to new pills.

Previously, Biden stated that he had doubled the government's order of Pfizer's Paxlovid, from 10 million to 20 million doses, while noting that it takes months to make a pill.

The federal government has been rationing monoclonal antibodies, which in any event are probably ineffective against the omicron variant, notes DDP.

The State of New York has received Paxlovid doses for treating only about 20,000 people. Its Health Commissioner Dr. Mary Bassett observed that that is insufficient.

Paxlovid is authorized by the FDA under an emergency use authorization (EUA). It contains a protease inhibitor, nirmatrelvir, to prevent viral replication plus the HIV drug ritonavir to prevent the protease inhibitor from being broken down. According to Pfizer press releases, Paxlovid has been effective in early treatment of mild to moderate COVID.

The Merck drug molnupiravir, which also has an EUA, could be available sooner. But because it results in genetic mutations, it is feared that it could lead to new viral variants or result in cancer or birth defects in humans.

Meanwhile, the government is hoarding in the Strategic National Stockpile some 60 million doses of hydroxychloroquine, which were donated by generous pharmaceutical companies to treat COVID-19. Hydroxychloroquine was FDA approved in 1955 and has been safely used by hundreds of millions of people for a variety of indications.

"Why is President Biden touting a medication that is mostly unavailable?" asks Dr. Orient. "And why is the government authorizing and recommending a medication that may be unsafe for many, while affordable, long-established drugs such as hydroxychloroquine and ivermectin are discouraged or suppressed?"

Doctors for Disaster Preparedness is a group of scientists (including physicians) founded in 1984, which provides information to help save lives in the event of natural or man-made disasters.

Contact: Jane M. Orient, M.D., (520) 323-3110, [email protected]

SOURCE Doctors for Disaster Preparedness


These press releases may also interest you

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...



News published on and distributed by: